PI Health Sciences Financial Overview

Growth momentum continues...vindicates differentiated business model and diversified product portfolio Pi Inspired by Science Revenue Figures in Rs. Million EBITDA PAT *Q3FY24 18,975 18% 5,550 34% 4,486 28% *YTM 9MFY24 59,248 20% 15,810 31% 13,120 38% Commercialised 4 new products in Exports and 5 in Domestic Agri Brands CSM Exports Order Book - USD ~1.7 billion Diversification in Pharma done, integration of CRO-CDMO-API platforms underway Trade working capital reduced from 90 days to 80 days 1st Indian company to get a new ISO approval "Pioxaniliprole" * Consolidated Financials 3

View entire presentation